Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.

Treatment of opioid use disorder (OUD) with buprenorphine improves outcomes and mortality among people with HIV (PWH). However, engagement is low and is influenced by comorbidities. We examined the impact of patterns of co-occurring pain, substance use disorders (SUDs), and mental health diagnoses o...

Descripción completa

Detalles Bibliográficos
Publicado en:AIDS & Behavior Vol. 28; no. 12; pp. 3994 - 4005
Autores principales: Miller, Emily A., McGinnis, Kathleen A., Edelman, E. Jennifer, Feinberg, Termeh, Gordon, Kirsha S., Kerns, Robert D., Marshall, Brandon D. L., Patterson, Julie A., McRae, MaryPeace
Formato: research tables/charts Journal Article
Publicado: Springer Nature Dec2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181065278&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 181065278
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        10907165
        G1T
      jtl: AIDS & Behavior
      issn: 10907165
      maglogo: N
    pubinfo:
      dt: Dec2024
      vid: 28
      iid: 12
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        181065278
        179588299
        181065278
        181065278
        10.1007/s10461-024-04494-w
        181065278
      ppf: 3994
      ppct: 11
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV.
      aug:
        au:
          Miller, Emily A.
          McGinnis, Kathleen A.
          Edelman, E. Jennifer
          Feinberg, Termeh
          Gordon, Kirsha S.
          Kerns, Robert D.
          Marshall, Brandon D. L.
          Patterson, Julie A.
          McRae, MaryPeace
        affil: https://ror.org/02nkdxk79 Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA
      sug:
        subj:
          HIV Infections Drug Therapy
          HIV Infections Epidemiology
          Buprenorphine Therapeutic Use
          Pain Drug Therapy
          Mental Health Evaluation
          Mental Disorders Drug Therapy
          Substance Use Disorders Drug Therapy
          Substance Use Disorders Epidemiology
          Pain Epidemiology
          Treatment Outcomes
          Human
          Funding Source
          Male
          Female
          United States
          Prospective Studies
          Nonexperimental Studies
          Structural Equation Modeling
          Veterans
          International Classification of Diseases
          Comorbidity
          Aging
          Regression
          Prescriptions, Drug
          HIV-Positive Persons Psychosocial Factors
          Analgesics, Opioid Therapeutic Use
          HIV Infections Complications
          Mental Disorders Complications
          Descriptive Statistics
          Male
          Female
      ab: Treatment of opioid use disorder (OUD) with buprenorphine improves outcomes and mortality among people with HIV (PWH). However, engagement is low and is influenced by comorbidities. We examined the impact of patterns of co-occurring pain, substance use disorders (SUDs), and mental health diagnoses on buprenorphine initiation and retention in PWH. The Veterans Aging Cohort Study contained 7,875 patients (2,702 PWH and 5,173 without HIV) with new OUD clinical encounters (2008–2017). Buprenorphine initiation and retention were derived from prescription data. We identified patterns of co-occurring diagnoses (via ICD codes) and assessed the effects of class membership on both outcomes using latent class analysis and regression analyses. The mean age of patients was 55, 98% were male, 58% Black, 8% Hispanic, and only 8% initiated buprenorphine within 12 months of OUD diagnosis. Four classes of co-occurring diagnoses were identified: "Few Co-occurring Diagnoses" (42.3%); "Multiple Pain Conditions" (21.3%); "Pain + SUD" (18.4%) and "Pain + SUD + Mental Health" (18.0%). Patients in the "Pain + SUD" class and "Pain + SUD + Mental Health" class were significantly less likely to initiate buprenorphine and had 59% and 45% lower odds, respectively, of initiating buprenorphine compared with patients in the "Few Co-occurring Diagnoses" class; this effect did not vary by HIV status. Buprenorphine retention was not significantly associated with HIV status or class membership. However, Black Veterans were less likely to initiate or be retained in buprenorphine treatment. Higher comorbidity burden was negatively associated with buprenorphine initiation but not with retention. More research is warranted to determine other factors that may influence treatment retention.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N